Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker ROIV
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Nov 13, 2026 amended | Richard Pulik Officer | ROIV Roivant Sciences Ltd. | 125,000 | $5.2M | — | Nov 10, 2026 | Form 4 ↗ -1 days later · 300,000 shares | Form 144/A ↗ |
| Nov 13, 2026 amended | Richard Pulik Officer | ROIV Roivant Sciences Ltd. | 175,000 | $7.3M | — | Nov 11, 2026 | Form 4 ↗ -1 days later · 300,000 shares | Form 144/A ↗ |
| Nov 12, 2026 | Richard Pulik Officer, Director | ROIV Roivant Sciences Ltd. | 175,000 | $7.3M | — | Nov 11, 2026 | Form 4 ↗ same day · 300,000 shares | Form 144 ↗ |
| Nov 10, 2026 | Eric Venker Officer | ROIV Roivant Sciences Ltd. | 187,943 | $7.6M | 10b5-1 | Nov 10, 2026 | Form 4 ↗ 2 days later · 187,943 shares | Form 144 ↗ |
| Nov 10, 2026 amended | Frank M Torti Officer | ROIV Roivant Sciences Ltd. | 1.23M | $50.7M | — | Nov 10, 2026 | — | Form 144/A ↗ |
| Nov 10, 2026 amended | Matthew Adam Gline Officer, Director | ROIV Roivant Sciences Ltd. | 164,136 | $6.7M | — | Nov 10, 2026 | — | Form 144/A ↗ |
| Nov 10, 2026 amended | Mayukh Sukhatme Officer, Director | ROIV Roivant Sciences Ltd. | 173,725 | $7.1M | — | Nov 10, 2026 | — | Form 144/A ↗ |
| Nov 10, 2026 | Mayukh Sukhatme Officer, Director | ROIV Roivant Sciences Ltd. | 173,725 | $7.1M | — | Nov 10, 2026 | — | Form 144 ↗ |
| Nov 10, 2026 | Matthew Adam Gline Officer, Director | ROIV Roivant Sciences Ltd. | 164,136 | $6.7M | — | Nov 10, 2026 | — | Form 144 ↗ |
| Nov 10, 2026 | Frank M Torti Officer | ROIV Roivant Sciences Ltd. | 1.23M | $50.7M | — | Nov 10, 2026 | — | Form 144 ↗ |
| Nov 10, 2026 | Richard Pulik Officer, Director | ROIV Roivant Sciences Ltd. | 125,000 | $5.2M | — | Nov 10, 2026 | Form 4 ↗ 2 days later · 300,000 shares | Form 144 ↗ |
| Nov 3, 2026 | Eric Venker Officer | ROIV Roivant Sciences Ltd. | 200,000 | $7.3M | 10b5-1 | Nov 3, 2026 | Form 4 ↗ 2 days later · 200,000 shares | Form 144 ↗ |
| Oct 28, 2026 | Eric Venker Officer | ROIV Roivant Sciences Ltd. | 200,000 | $7.3M | 10b5-1 | Oct 28, 2026 | Form 4 ↗ 2 days later · 200,000 shares | Form 144 ↗ |
| Oct 20, 2026 | Eric Venker Officer | ROIV Roivant Sciences Ltd. | 200,000 | $7.0M | 10b5-1 | Oct 20, 2026 | Form 4 ↗ 2 days later · 200,000 shares | Form 144 ↗ |
| Sep 30, 2026 | Eric Venker Officer | ROIV Roivant Sciences Ltd. | 200,000 | $7.3M | 10b5-1 | Sep 30, 2026 | Form 4 ↗ 22 days later · 200,000 shares | Form 144 ↗ |
| Sep 15, 2026 | Melissa Epperly Director | ROIV Roivant Sciences Ltd. | 22,688 | $930.7K | 10b5-1 | Sep 15, 2026 | Form 4 ↗ 2 days later · 4,938 shares | Form 144 ↗ |
| Sep 15, 2026 | Meghan Fitzgerald Officer | ROIV Roivant Sciences Ltd. | 5,112 | $209.7K | 10b5-1 | Sep 15, 2026 | Form 4 ↗ 2 days later · 5,112 shares | Form 144 ↗ |
| Sep 8, 2026 | Meghan Fitzgerald Director | ROIV Roivant Sciences Ltd. | 20,000 | $698.6K | 10b5-1 | Sep 8, 2026 | Form 4 ↗ 2 days later · 20,000 shares | Form 144 ↗ |
| Aug 28, 2026 | Eric Venker Officer | ROIV Roivant Sciences Ltd. | 200,000 | $7.1M | 10b5-1 | Aug 28, 2026 | Form 4 ↗ 4 days later · 200,000 shares | Form 144 ↗ |
| Aug 21, 2026 | Mayukh Sukhatme Officer, Director | ROIV Roivant Sciences Ltd. | 144,756 | $5.3M | — | Aug 21, 2026 | Form 4 ↗ same day · 335,174 shares | Form 144 ↗ |
| Aug 20, 2026 | Mayukh Sukhatme Officer, Director | ROIV Roivant Sciences Ltd. | 17,519 | $653.4K | — | Aug 20, 2026 | Form 4 ↗ 1 day later · 335,174 shares | Form 144 ↗ |
| Aug 19, 2026 | Mayukh Sukhatme Officer, Director | ROIV Roivant Sciences Ltd. | 172,899 | $6.4M | — | Aug 19, 2026 | Form 4 ↗ 2 days later · 335,174 shares | Form 144 ↗ |
| Aug 18, 2026 | Mayukh Sukhatme Officer, Director | ROIV Roivant Sciences Ltd. | 136,942 | $5.0M | — | Aug 18, 2026 | Form 4 ↗ same day · 421,649 shares | Form 144 ↗ |
| Aug 17, 2026 | Mayukh Sukhatme Officer, Director | ROIV Roivant Sciences Ltd. | 284,707 | $10.3M | — | Aug 17, 2026 | Form 4 ↗ 1 day later · 664,826 shares | Form 144 ↗ |
| Aug 14, 2026 | Mayukh Sukhatme Officer, Director | ROIV Roivant Sciences Ltd. | 243,177 | $8.8M | — | Aug 14, 2026 | Form 4 ↗ 4 days later · 664,826 shares | Form 144 ↗ |
| Jul 27, 2026 | Eric Venker Officer | ROIV Roivant Sciences Ltd. | 200,000 | $7.0M | 10b5-1 | Jul 27, 2026 | Form 4 ↗ 2 days later · 200,000 shares | Form 144 ↗ |
| Jun 30, 2026 | Meghan Fitzgerald Director | ROIV Roivant Sciences Ltd. | 10,000 | $347.3K | 10b5-1 | Jun 30, 2026 | Form 4 ↗ 2 days later · 10,000 shares | Form 144 ↗ |
| Jun 30, 2026 | Keith S Manchester Director | ROIV Roivant Sciences Ltd. | 200,000 | $7.1M | — | Jun 30, 2026 | Form 4 ↗ same day · 1.01M shares | Form 144 ↗ |
| Jun 29, 2026 | Melissa Epperly Director | ROIV Roivant Sciences Ltd. | 17,750 | $604.7K | 10b5-1 | Jun 29, 2026 | Form 4 ↗ 2 days later · 17,750 shares | Form 144 ↗ |
| Jun 26, 2026 | Mayukh Sukhatme Officer, Director | ROIV Roivant Sciences Ltd. | 500,000 | $17.0M | — | Jun 26, 2026 | Form 4 ↗ 3 days later · 1.00M shares | Form 144 ↗ |
| Jun 25, 2026 | Mayukh Sukhatme Officer, Director | ROIV Roivant Sciences Ltd. | 500,000 | $17.1M | — | Jun 25, 2026 | Form 4 ↗ 4 days later · 1.00M shares | Form 144 ↗ |
| Jun 24, 2026 | Eric Venker Officer | ROIV Roivant Sciences Ltd. | 200,000 | $6.6M | 10b5-1 | Jun 24, 2026 | Form 4 ↗ 2 days later · 200,000 shares | Form 144 ↗ |
| May 22, 2026 | Eric Venker Officer | ROIV Roivant Sciences Ltd. | 200,000 | $6.1M | 10b5-1 | May 22, 2026 | Form 4 ↗ same day · 200,000 shares | Form 144 ↗ |
| Apr 20, 2026 | Eric Venker Officer | ROIV Roivant Sciences Ltd. | 200,000 | $5.9M | 10b5-1 | Apr 20, 2026 | Form 4 ↗ 2 days later · 200,000 shares | Form 144 ↗ |
| Apr 16, 2026 amended | Matthew Gline Officer | ROIV Roivant Sciences Ltd. | 289,774 | $8.4M | — | Apr 16, 2026 | Form 4 ↗ 4 days later · 289,774 shares | Form 144/A ↗ |
| Apr 16, 2026 | Matthew Gline Officer | ROIV Roivant Sciences Ltd. | 289,774 | $8.4M | — | Apr 16, 2026 | Form 4 ↗ 4 days later · 289,774 shares | Form 144 ↗ |
| Apr 8, 2026 | Jennifer Humes Officer | ROIV Roivant Sciences Ltd. | 13,538 | $384.0K | — | Apr 8, 2026 | Form 4 ↗ 2 days later · 13,538 shares | Form 144 ↗ |
| Mar 26, 2026 | Meghan Fitzgerald Director | ROIV Roivant Sciences Ltd. | 70,000 | $1.9M | — | Mar 26, 2026 | Form 4 ↗ 4 days later · 70,000 shares | Form 144 ↗ |
| Mar 17, 2026 | Eric Venker Officer | ROIV Roivant Sciences Ltd. | 200,000 | $5.6M | 10b5-1 | Mar 17, 2026 | Form 4 ↗ 2 days later · 200,000 shares | Form 144 ↗ |
| Mar 16, 2026 | Melissa B Epperly Director | ROIV Roivant Sciences Ltd. | 41,861 | $1.2M | — | Mar 16, 2026 | Form 4 ↗ 2 days later · 41,861 shares | Form 144 ↗ |
| Feb 20, 2026 | Frank Torti Officer | ROIV Roivant Sciences Ltd. | 1.60M | $44.0M | 10b5-1 | Feb 20, 2026 | Form 4 ↗ 3 days later · 3.00M shares | Form 144 ↗ |
| Feb 19, 2026 | Frank Torti Officer | ROIV Roivant Sciences Ltd. | 1.40M | $38.5M | 10b5-1 | Feb 19, 2026 | Form 4 ↗ 4 days later · 3.00M shares | Form 144 ↗ |
| Feb 13, 2026 | Eric Venker Officer | ROIV Roivant Sciences Ltd. | 200,000 | $5.3M | 10b5-1 | Feb 13, 2026 | Form 4 ↗ 5 days later · 200,000 shares | Form 144 ↗ |
| Feb 9, 2026 | Sukhatme Mayukh Officer | ROIV Roivant Sciences Ltd. | 339,441 | $9.0M | — | Feb 9, 2026 | Form 4 ↗ 2 days later · 339,441 shares | Form 144 ↗ |
| Jan 12, 2026 | Eric Venker Officer | ROIV Roivant Sciences Ltd. | 200,000 | $4.4M | 10b5-1 | Jan 12, 2026 | Form 4 ↗ 2 days later · 200,000 shares | Form 144 ↗ |
| Dec 31, 2025 | Sukhatme Mayukh Officer | ROIV Roivant Sciences Ltd. | 1.02M | $22.1M | — | Dec 31, 2025 | Form 4 ↗ same day · 1.33M shares | Form 144 ↗ |
| Dec 29, 2025 | Sukhatme Mayukh Officer | ROIV Roivant Sciences Ltd. | 311,873 | $6.8M | — | Dec 29, 2025 | Form 4 ↗ 2 days later · 1.33M shares | Form 144 ↗ |
| Dec 29, 2025 | Eric Venker Officer | ROIV Roivant Sciences Ltd. | 75,000 | $1.7M | — | Dec 24, 2025 | Form 4 ↗ 16 days later · 200,000 shares | Form 144 ↗ |
| Dec 29, 2025 | Frank M Torti Officer, Director | ROIV Roivant Sciences Ltd. | 64,891 | $1.5M | — | Dec 24, 2025 | Form 4 ↗ 56 days later · 3.00M shares | Form 144 ↗ |
| Dec 23, 2025 | Richard Pulik Officer | ROIV Roivant Sciences Ltd. | 260,000 | $5.8M | — | Dec 23, 2025 | Form 4 ↗ 6 days later · 406,731 shares | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 6:21 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances